"Heat transformation" is one of the important pathogenesis of coronary heart disease, but in the past, more attention was paid to "yang insufficient and yin strings" of chest arthralgia and less attention was paid to it. In the Inner Canon of Yellow Emperor, there are descriptions of heat related to "heart disease" and "heart ache". On the basis of summing up the clinical experience and academic thought of National TCM Masters, Mei Guoqiang, Zhou Zhongying, Chen Keji, Zhang Xuewen, Duan Fujin, Lei Zhongyi, Li Shimao, Qiu Peiran and Su Rongzabu in treating coronary heart disease from heat, we concluded 4 main types of pathogenesis of coronary heart disease of phlegm-dampness-depression and heat-inducing, stagnation of blood stasis and heat, retention of toxic heat in the interior and yin-deficiency induced heat. The key points of differentiation and treatment were refined. For phlegm-dampness-depression and heat-inducing, the differentiation of tongue and pulse should be focused, and the treatment should be heat-clearing and phlegm-resolving. The commonly used prescription was Xianxiong Decoction with Periostracum Cicadae, Rhizoma et Radix Notopterygii, Herba Schizonepetae, Radix Saposhnikoviae, Herba Menthae, Radix Puerariae and other anti-heat drugs; For stagnation of blood stasis and heat, the blood stasis and heat was differentiated, and it is important to treat with "cool" and "disperse". Xijiao Dihuang Decoction was mainly used to clear heat and cool blood; For retention of toxic heat in the interior, the illness is serious, and it should be treated with heat-clearing and detoxifying Chinese herbs such as Simiao Yong"an Decoction with clearing heat and cooling blood herbs of Fructus Forsythiae and Rhizoma Polygoni Cuspidati; For yin-deficiency inducing heat, the heart and kidney should be differentiated. Shengmai Powder with Radix Rehmanniae Recens was commonly used to nourish heart and kidney yin. In order to further improve the theoretical system of coronary heart disease and improve the clinical efficacy, the combination of disease and syndrome and the treatment of disease and mechanism should be considered.
＊ 科学技术部国家重点基础研究计划“973计划” 2014CB542903;中央级公益性科研院所基本科研业务费中国中医科学院基础所自主选题项目（No.YZ1816）：重组高密度脂蛋白 pHDL＊ 科学技术部国家重点基础研究计划“973计划”（2014CB542903）：中医证候临床辨证的基础研究，负责人：胡镜清；中央级公益性科研院所基本科研业务费中国中医科学院基础所自主选题项目（No.YZ1816）：重组高密度脂蛋白（pHDL）包载白藜芦醇靶向治疗动脉粥样硬化的研究，负责人：李子贇。